Reports of Biochemistry
and Molecular Biology
Thu, Nov 21, 2024
[Archive]
Volume 13, Issue 1 (Vol.13 No.1 Apr 2024)
rbmb.net 2024, 13(1): 99-105 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Khudhyer Abbas H, Oied Saleh B, Habeeb Ghali H. Role of Serum Interleukin-10 and Interleukin-27 Levels in the Prognosis of Immune Thrombocytopenia in Iraqi Children. rbmb.net 2024; 13 (1) :99-105
URL: http://rbmb.net/article-1-1364-en.html
URL: http://rbmb.net/article-1-1364-en.html
College of Medicine, University of Baghdad, Baghdad, Iraq
Abstract: (401 Views)
Background: Several studies provide evidence for a role of serum cytokines imbalance including IL-10 and IL-27 in immune thrombocytopenia pathogenesis and prognosis. The aim of this study was designed to investigate the role of serum levels of IL-10 and IL-27 in prognosis the efficiency of treatment in thrombocytopenic Iraqi children
Methods: This case controls study was carried out at Department of Biochemistry, College of Medicine, University of Baghdad, during the period from October 2023 to March 2024. It included 88 children, 63 children previously diagnosed with immune thrombocytopenia, and 25 apparently healthy children who served as control group. The included immune thrombocytopenic children were sub-grouped according to their treatment into three groups: Romiplostim group (group 1), Prednisolone group (group 2), Prednisolone and intravenous immunoglobulin (IVIG) or Prednisolone and mycophenolate group (group 3). Investigations included serum level measurements of IL-10 and IL-27 by using enzyme linked immunosorbent assay ELISA. Platelet count of each included children was measured by Huma Count 30 TS Human, Germany.
Results: The mean (±SEM) values of serum IL-10 and IL-27 levels of immune thrombocytopenic children were insignificantly lower than that of controls. In addition, there was non- significant differences in serum levels of IL-10 and IL-27 among and between the three groups of patient children. The mean value of platelet count of patient children was significantly increased by all types of treatment in whole immune thrombocytopenic children (117.48±18.15*10^9/L).
Conclusion: Measurement of serum IL-10 and IL-27 are helpful biomarker in prognosis of thrombocytopenia irrespective of type of treatment.
Methods: This case controls study was carried out at Department of Biochemistry, College of Medicine, University of Baghdad, during the period from October 2023 to March 2024. It included 88 children, 63 children previously diagnosed with immune thrombocytopenia, and 25 apparently healthy children who served as control group. The included immune thrombocytopenic children were sub-grouped according to their treatment into three groups: Romiplostim group (group 1), Prednisolone group (group 2), Prednisolone and intravenous immunoglobulin (IVIG) or Prednisolone and mycophenolate group (group 3). Investigations included serum level measurements of IL-10 and IL-27 by using enzyme linked immunosorbent assay ELISA. Platelet count of each included children was measured by Huma Count 30 TS Human, Germany.
Results: The mean (±SEM) values of serum IL-10 and IL-27 levels of immune thrombocytopenic children were insignificantly lower than that of controls. In addition, there was non- significant differences in serum levels of IL-10 and IL-27 among and between the three groups of patient children. The mean value of platelet count of patient children was significantly increased by all types of treatment in whole immune thrombocytopenic children (117.48±18.15*10^9/L).
Conclusion: Measurement of serum IL-10 and IL-27 are helpful biomarker in prognosis of thrombocytopenia irrespective of type of treatment.
Type of Article: Original Article |
Subject:
Biochemistry
Received: 2024/03/30 | Accepted: 2024/07/22 | Published: 2024/10/22
Received: 2024/03/30 | Accepted: 2024/07/22 | Published: 2024/10/22
References
1. Grodzielski M, Goette NP, Glembotsky AC, Constanza Baroni Pietto M, Méndez-Huergo SP, Pierdominici MS, et al. Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia. Sci Rep. 2019;9(1):1-10. [DOI:10.1038/s41598-018-38086-1] [PMID] []
2. Jaime-Pérez JC, Aguilar-Calderón P, Jiménez-Castillo RA, Ramos-Dávila EM, Salazar-Cavazos L, Gómez-Almaguer D. Treatment outcomes and chronicity predictors for primary immune thrombocytopenia: 10-year data from an academic center. Ann Hematol. 2020; 99:2513-20. [DOI:10.1007/s00277-020-04257-2] [PMID]
3. Park YH, Kim DY, Kim S, Choi YB, Shin DY, Kim JS, et al. Management of immune thrombocytopenia: 2022 update of Korean experts recommendations. Blood Res. 2022;57(1):20-8. [DOI:10.5045/br.2022.2022043] [PMID] []
4. Kuter DJ. The treatment of immune thrombocytopenia (ITP)-focus on thrombopoietin receptor agonists. Ann Blood. 2021; 6:5-21. [DOI:10.21037/aob-21-23]
5. Provan D, Newland AC. Current Management of Primary Immune Thrombocytopenia. Adv Ther. 2015;32(10):875-87. [DOI:10.1007/s12325-015-0251-z] [PMID] []
6. Neunert CE, Rose MJ. Romiplostim for the management of pediatric immune thrombocytopenia: Drug development and current practice. Blood Adv. 2019;3(12):1907-15. [DOI:10.1182/bloodadvances.2019000279] [PMID] []
7. Zhou H, Qiu JH, Wang T, Yu Y Y, Liu XN, Li X, et al. Interleukin 27 inhibits cytotoxic T-lymphocyte-mediated platelet destruction in primary immune thrombocytopenia. 2014;124(22):3316-9. [DOI:10.1182/blood-2014-06-580084] [PMID] []
8. Liu XG, Ren J, Yu Y, Sun L, Shi Y, Qin P, et al. Decreased expression of interleukin‐27 in immune thrombocytopenia. Br J Haematol. 2011;153(2):259-67. [DOI:10.1111/j.1365-2141.2011.08614.x] [PMID]
9. Wei AH, Schoenwaelder SM, Andrews RK, Jackson SP. New insights into the haemostatic function of platelets. 2009; 147(4):415-30. [DOI:10.1111/j.1365-2141.2009.07819.x] [PMID]
10. Sheikhpour E, Noorbakhsh P, Foroughi E, Farahnak S, Nasiri R, Neamatzadeh H. A survey on the role of interleukin-10 in breast cancer: A narrative. Reports Biochem Mol Biol. 2017;7(1):30-37.
11. Miresmaeili Mazrakhondi SA, Zare-Zardini H. Comparison of Serum Changes of Interleukin-17A and Interleukin-21 Between Schizophrenic Patients and Healthy Individuals. Rep Biochem Mol Biol. 2022;11(3):465-470. [DOI:10.52547/rbmb.11.3.465] [PMID] []
12. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011; 29:71-109. [DOI:10.1146/annurev-immunol-031210-101312] [PMID]
13. AL- Obeidy ESh, Al.Obeidy AH, Asker BA. Viruses as a Trigger for autoimmune Hepatitis in susceptible Individual. Vol. 50, J Fa Med Baghdad. 2008;50 (4): 471-4. [DOI:10.32007/jfacmedbagdad.5041233]
14. Nazar Hasan Anber Z, Oead Mohammed Saleh B, Waheab Al-Obidy M. Hepatocellular Damage and Severity of COVID-19 Infection in Iraqi Patients: A Biochemical Study. Rep Biochem Mol Biol. 2022;11(3):524-531. [DOI:10.52547/rbmb.11.3.524] [PMID] []
15. Rostami-Far Z, Rahmani K, Mansouri K, Khadem Erfan MB, Shaveisi-Zadeh F, Nikkhoo B. Genetic Regulation of Interleukin-6 and Interleukin-10 in COVID-19 Infection. Rep Biochem Mol Biol. 2023;12(2):284-293. [DOI:10.61186/rbmb.12.2.284] [PMID] []
16. Althwani AN, Najm MA. The Role of Interleukin-10 in Women with Metastatic Invasive Ductal Carcinoma. J Fac Med Baghdad. 2011;53(3):289-92. [DOI:10.32007/jfacmedbagdad.533831]
17. Liu Q, Liu Y. Role of IL-10 and IL-22 cytokines in patients with primary immune thrombocytopenia and their clinical significance. J Clin Lab Anal. 2022;36(8): e24573. [DOI:10.1002/jcla.24573] [PMID] []
18. Chaloob AK. Correlation of interleukin 6 (IL-6) with estrogen and progesterone receptor expression in breast cancer patients. J Fac Med Baghdad. 2011;52(4):438-40. [DOI:10.32007/jfacmedbagdad.524952]
19. Hassan T, Khalil A, Raafat N, Metwally U, Rahman DA. Contribution of Serum Interleukin-10 to the Pathogenesis of Primary Immune Thrombocytopenia in Egyptian Children: A Single Center Experience. Egypt J Hosp Med. 2022;87(1):2046-51. [DOI:10.21608/ejhm.2022.232265]
20. Heitink-Pollé KM, Nijsten J, Boonacker CW, de Haas M, Bruin MC. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis. Blood. 2014;124(22):3295-307. [DOI:10.1182/blood-2014-04-570127] [PMID]
21. Čulić S, Salamunić I, Konjevoda P, Dajak S, Pavelić J. Immune thrombocytopenia: Serum cytokine levels in children and adults. Med Sci Monit. 2013;19(1):797-801. [DOI:10.12659/MSM.884017] [PMID] []
22. Carter NA, Rosser EC, Mauri C. Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res Ther. 2012;14(1):1-9. [DOI:10.1186/ar3736] [PMID] []
23. Apovian CM, Okemah J, O'Neil PM. Body Weight Considerations in the Management of Type 2 Diabetes. Adv Ther. 2019;36(1):44-58. [DOI:10.1007/s12325-018-0824-8] [PMID] []
24. AL-Najy MH, AL-Joofy KK, AL-Marayati AN. Production of Inflammatory Markers (IL-8, IL-4and IFN-g) and risk of Ischemic Hart Diseases. J Fac Med Baghdad. 2010;52(2):186-9. [DOI:10.32007/jfacmedbagdad.5221020]
25. Maulan Mohammed A, Zayni SM, AL-Anee MM, Isho Corial F, Al- Rubaee A. Diagnostic and Predictive Values of IL-6 in a Group of Iraqi Patients with Rheumatoid Arthritis. J Fac Med Baghdad. 2023;65(2): :116-121. [DOI:10.32007/jfacmedbagdad.2044]
26. Jaafar IF, Ahmed MH, alsalihi AR. Effect of Body mass index on interleukin2, 6 and soluble fibroblast associated surface antigen in infertile men. J Fac Med Baghdad.2014;56(4):426-30.
https://doi.org/10.32007/jfacmedbagdad.564561 [DOI:10.32007/med.1936/jfacmedbagdad.v56i4.18]
27. Abdulla AR, Mohammed Ali AH, Al-Rawaq KJ, Ibraheem AN. IL-10 serum level estimation in Iraqi colorectal and gastric cancer patients. J Fac Med Baghdad. 2012;54(2):167-71. [DOI:10.32007/jfacmedbagdad.542750]
28. Hassan T, Abdel Rahman D, Raafat N, Fathy M, Shehab M, Hosny A, et al. Contribution of interleukin 27 serum level to pathogenesis and prognosis in children with immune thrombocytopenia. Medicine (Baltimore). 2022; 101(25): E29504. [DOI:10.1097/MD.0000000000029504] [PMID] []
29. Franzoso FD, Schmugge M. Increased levels of IL-10 and IL-1Ra counterbalance the proinflammatory cytokine pattern in acute pediatric immune thrombocytopenia. Cytokine. 2020; 130:155078. [DOI:10.1016/j.cyto.2020.155078] [PMID]
30. Del Vecchio GC, Giordano P, Tesse R, Piacente L, Altomare M, De Mattia D. Clinical significance of serum cytokine levels and thrombopoietic markers in childhood idiopathic thrombocytopenic purpura. Blood Transfus. 2012;10(2):194-9.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
